Compare PRGS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGS | CDNA |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1995 | 2007 |
| Metric | PRGS | CDNA |
|---|---|---|
| Price | $42.89 | $47.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $49.50 | $28.00 |
| AVG Volume (30 Days) | 532.6K | ★ 1.3M |
| Earning Date | 03-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.79 | N/A |
| EPS | 1.03 | ★ 2.13 |
| Revenue | ★ $397,572,000.00 | $48,324,000.00 |
| Revenue This Year | $3.70 | $16.01 |
| Revenue Next Year | $1.08 | $11.31 |
| P/E Ratio | $42.05 | ★ $22.15 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $23.82 | $11.27 |
| 52 Week High | $47.37 | $49.76 |
| Indicator | PRGS | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 64.40 | 74.96 |
| Support Level | $41.79 | $16.70 |
| Resistance Level | $43.97 | $49.76 |
| Average True Range (ATR) | 1.66 | 2.23 |
| MACD | 0.05 | 0.42 |
| Stochastic Oscillator | 86.12 | 85.15 |
Progress Software Corp provides software products that enable customers to develop, deploy, and manage AI-powered applications and digital experiences. The Company operates across North America, Latin America, Europe, the Middle East and Africa (EMEA), and Asia Pacific through subsidiaries and distributors, generating a majority of its revenue from the United States. Its product portfolio includes Progress Agentic RAG, Automate MFT, Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, and WhatsUp Gold, offering solutions for application development, data connectivity, DevOps automation, managed file transfer, network security, and digital experience. It generates maximum revenue from the United States.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.